The group's principal activity is to develop, acquire and market treatments for cancer. The products of the group include trisenox that is marketed for patients with a type of blood cell cancer called acute promyelocytic leukemia, or apl. The fda to treat patients who have relapsed or refractory acute promyelocytic leukemia has approved trisenox, a pharmaceutical grade arsenic product. The principal products of the group are trisenox, pg-txl, pg- cpt and ct-2584. On 1-Jan-2004 the group acquired novuspharma s.p.a.
